CAZZANIGA MARINA ELENA

Cazzaniga, M., Cogliati, V., Rossi, E., Paris, I., Borella, F., Moretti, G., et al. (2026). Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study. ESMO REAL WORLD DATA AND DIGITAL ONCOLOGY, 11(March 2026) [10.1016/j.esmorw.2025.100665]. Dettaglio

Bianchini, G., Malorni, L., Caputo, R., Zambelli, A., Puglisi, F., Bianchi, G., et al. (2026). Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial. CLINICAL CANCER RESEARCH, 32(12), 2428-2437 [10.1158/1078-0432.CCR-25-0650]. Dettaglio

Franco, G., Promi, S., Galbardi, I., Paciocco, G., Allegranza, P., Cangiotti, C., et al. (2026). A hypermetabolic pulmonary lesion in a patient with breast cancer. BREATHE, 22(2) [10.1183/20734735.0042-2026]. Dettaglio

Ilari, A., Grassilli, E., Mauri, M., Cazzaniga, M., Capici, S., Lavitrano, M., et al. (2026). Metronomic 5-Fluorouracil and Vinorelbine Reduce Cancer Stemness and Modulate EZH2/NOTCH-1/STAT3 Signaling in Triple-Negative Breast Cancer Spheroids. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 27(1) [10.3390/ijms27010123]. Dettaglio

Garrigos, L., Ruiz-Borrego, M., Perez-Garcia, J., Guerrero-Zotano, A., Cortes-Salgado, A., Kuemmel, S., et al. (2026). A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study☆. ANNALS OF ONCOLOGY, 37(6), 837-848 [10.1016/j.annonc.2026.01.013]. Dettaglio